Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies
- PMID: 35953132
- DOI: 10.1016/j.jacc.2022.06.007
Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies
Keywords: Alzheimer’s disease; HMGCR; Mendelian randomization; PCSK9; dementia; neurocognition.
Conflict of interest statement
Funding Support and Author Disclosures Dr Ference has received research grants from Novartis, Amgen, Merck, Pfizer, and Esperion Therapeutics; and has received personal fees for consulting, Advisory Board participation, and lectures from Novartis, Amgen, Regeneron, Sanofi, Merck, Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, Viatris, The Medicines Co, Mylan, Daiichi-Sankyo, dalCOR, CiVi Pharma, KrKa Pharmaceuticals, the American College of Cardiology, the European Society of Cardiology, and the European Atherosclerosis Society.
Comment on
-
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.J Am Coll Cardiol. 2022 Aug 16;80(7):653-662. doi: 10.1016/j.jacc.2022.05.041. J Am Coll Cardiol. 2022. PMID: 35953131
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous